机构：[1]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China四川省人民医院四川省肿瘤医院
Objectives This study aimed to explore the expression profile of the Forkhead box protein L2 gene (FOXL2) and to determine its prognostic value and associated epigenetic and genetic alterations in patients with laryngeal squamous cell carcinoma (LSCC). Materials and methods Data for a subset of patients with LSCC (N = 116) were extracted from the head and neck squamous cell carcinoma dataset of The Cancer Genome Atlas and analyzed in relation to FOXL2 expression and survival. Results Aberrant FOXL2 expression was an independent prognostic factor for progression-free survival (PFS) (hazard ratio (HR): 2.63, 95% confidence interval (CI): 1.34-5.18) and overall survival (OS) (HR: 2.39, 95%CI: 1.28-4.46). Two gene-body CpG sites (cg10554436 and cg23637494) were moderately and positively correlated with FOXL2 expression. DNA amplification (+2/+1) was common (82/115, 71%) in LSCC, and FOXL2 expression was significantly upregulated in the high-amplification group (+2) compared with copy-neutral (0) cases. Conclusion Aberrant FOXL2 expression may be a novel prognostic biomarker for PFS and OS among patients with LSCC. FOXL2 upregulation may be related to gene-body hypermethylation and DNA amplification.
基金：
This work was financially supported by Beijing
Xisike Clinical Oncology Research Foundation
(Y-XD2019-201) and the Foundation of Science
and Technology Department of Sichuan
Province (2019YJ0583).
基金编号：Y-XD2019-201
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
最新[2023]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
JCR分区：
出版当年[2020]版：
Q4PHARMACOLOGY & PHARMACYQ4MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q4MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
第一作者机构：[1]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
通讯作者：
通讯机构：[1]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China[*1]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 4th Section, People’s South Road, Chengdu, 610041, Sichuan, China.
推荐引用方式(GB/T 7714)：
Jun Ge,Li Jiang,Yuke Tian,et al.FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal squamous cell carcinoma[J].JOURNAL OF INTERNATIONAL MEDICAL RESEARCH.2020,48(4):doi:10.1177/0300060520919252.
APA：
Jun Ge,Li Jiang,Yuke Tian,Min Zheng,Meiling Huang&Juan Li.(2020).FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal squamous cell carcinoma.JOURNAL OF INTERNATIONAL MEDICAL RESEARCH,48,(4)
MLA：
Jun Ge,et al."FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal squamous cell carcinoma".JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 48..4(2020)
